HR 383
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill aims to reverse changes made by the Food and Drug Administration (FDA) in January 2023 regarding the availability of mifepristone, a medication used in abortion care. The FDA’s modifications removed the requirement that mifepristone be dispensed in person and instead allowed certified pharmacies to fill prescriptions. This bill seeks to restore the previous requirement for in-person dispensing and prevent similar changes to the medication’s risk evaluation and mitigation strategy in the future.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.